IBRX - Latest News
ImmunityBio, Inc. (IBRX), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $8.54B. Beta to the broader market is 0.07.
The article list below shows the most recent IBRX headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent IBRX Headlines
ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc. - IBRX
gurufocus.com - May 15, 2026
ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsu
ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc. - IBRX
prnewswire.com - May 15, 2026
NEW ORLEANS, May 15, 2026 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until May 26, 2026 to
IBRX INVESTOR NOTICE: ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman
globenewswire.com - May 15, 2026
SAN FRANCISCO, May 15, 2026 (GLOBE NEWSWIRE) -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent inv
IBRX Shareholder Alert: ImmunityBio, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law Firm
globenewswire.com - May 15, 2026
NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of ImmunityBio, Inc. (NASDAQ: IBRX).
IBRX Shareholder Alert: ImmunityBio, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law Firm
globenewswire.com - May 15, 2026
NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of ImmunityBio, Inc. (NASDAQ: IBRX).
How News Affects IBRX Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track IBRX's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked IBRX news questions
- What is the latest IBRX news headline?
- The most recent IBRX headline (May 15, 2026) is "ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc. - IBRX". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the IBRX news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What IBRX news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual IBRX options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.